NCT03794349 2026-02-18Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory NeuroblastomaChildren's Oncology GroupPhase 2 Active not recruiting94 enrolled 14 charts